Meeting with the Chairpersons of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association

The National Bioinnovation Committee (the Committee) held a meeting with the Chairpersons of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association on June 15 at Seoul Square in Jung-gu, Seoul, where they listened to on-site feedback aimed at fostering an innovative ecosystem for the domestic pharmaceutical and bio industry and strengthening global competitiveness.


This meeting marked the first official communication with the pharmaceutical and bio industry sector. It was organized to systematically identify and implement key tasks by continuously reflecting the needs of the field and strengthening public-private cooperation.


Officials from the National Bioinnovation Committee and the Board of Directors of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association are taking a commemorative photo after holding a meeting on the 15th at Seoul Square in Jung-gu, Seoul. Korea Pharmaceutical and Bio-Pharma Manufacturers Association

Officials from the National Bioinnovation Committee and the Board of Directors of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association are taking a commemorative photo after holding a meeting on the 15th at Seoul Square in Jung-gu, Seoul. Korea Pharmaceutical and Bio-Pharma Manufacturers Association

View original image

The meeting was attended by key officials from the Committee, including Vice Chairperson Won Heemok, as well as major CEOs from pharmaceutical and bio companies, including Noh Yeonhong, Chairman of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, who exchanged a wide range of opinions on the development of the industry.


CEOs of pharmaceutical and bio companies presented their perspectives on policy proposals and regulatory improvements to enhance the industry’s competitiveness and vitality, as well as difficulties they experience in the field. The Committee listened closely and discussed practical support measures and directions for collaboration.


The participants shared a broad range of views on key industry issues such as promoting R&D, creating an innovative ecosystem for new drug development, revitalizing open innovation, improving the investment environment for research and development, strengthening global production and export competitiveness, and expanding the foundation for the stable supply of essential medicines. They also discussed ways to promote innovation in research and development using artificial intelligence (AI) and various strategies to further enhance industrial competitiveness.


Both sides agreed on the need for close cooperation between the government and the industry to advance the innovation ecosystem and for policy support to help domestic companies secure competitiveness in the global market, especially as global bio competition intensifies.


Vice Chairperson Won Heemok stated, "As the National Bioinnovation Committee is a single governance body overseeing and coordinating pharmaceutical and bio policies, it will serve as a platform for industry innovation. We will continue to communicate with the pharmaceutical and bio industry sector and, together with the relevant ministries, seek effective support measures to ensure the industry's capabilities translate into global competitiveness."


Chairman Noh Yeonhong commented, "Today's meeting was a meaningful occasion to share vivid on-site opinions with the government and seek solutions together. I hope that the industry’s various proposals—such as innovation in new drug development, revitalizing investment, and expanding global reach—will be faithfully reflected in policies, thereby boosting industrial competitiveness and accelerating our leap onto the global stage."



The Committee was represented at the meeting by Vice Chairperson Won Heemok; Yang Seongil, Chairperson of the Regulatory Special Committee; Kim Kunyeon, Head of the Support Group; Lee Youngho, Director of Technology Innovation; Yoon Sunghoon, Director of Investment Strategy; and Kim Sanghee, Director of Industrial Promotion. From the Association, attendees included Chairman Noh Yeonhong; Kim Youngjoo, President of Chong Kun Dang; Kim Utae, Chairman of Guju Pharmaceutical; Son Jiwung, President of LG Chem; Shin Youngsub, President of JW Pharmaceutical; Ahn Jaeyong, President of SK Bioscience; Yoon Sungtae, Chairman of Huons Group; Yoon Woongseop, Chairman of IlDong Pharmaceutical; Jeong Jaehoon, CEO of DongA ST; Cho Wookje, President of Yuhan Corporation; Hwang Sangyeon, CEO of Hanmi Pharmaceutical; as well as Lee Jaeguk, Vice Chairman of the Association, and Eom Seungin, Executive Director.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing